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Effectiveness of Self-guided App-Based Virtual Reality
Cognitive Behavior Therapy for Acrophobia:
A Randomized Clinical Trial
Tara Donker, PhD; Ilja Cornelisz, PhD; Chris van Klaveren, PhD; Annemieke van Straten, PhD;
Per Carlbring, PhD; Pim Cuijpers, PhD; Jean-Louis van Gelder, PhD
IMPORTANCE Globally, access to evidence-based psychological treatment is limited.
Innovative self-help methods using smartphone applications and low-cost virtual reality have
the potential to significantly improve the accessibility and scalability of psychological
treatments.
OBJECTIVE To examine the effectiveness of ZeroPhobia, a fully self-guided app-based virtual
reality cognitive behavior therapy (VR CBT) using low-cost (cardboard) virtual reality goggles
compared with a wait-list control group and to determine its user friendliness.
DESIGN, SETTING, AND PARTICIPANTS In a single-blind randomized clinical trial, participants
were enrolled between March 24 and September 28, 2017, and randomly assigned (1:1) by
an independent researcher to either VR CBT app or a wait-list control group. A total of 193
individuals aged 18 to 65 years from the Dutch general population with acrophobia symptoms
and access to an Android smartphone participated. The 6 animated modules of the VR-CBT
app and gamified virtual reality environments were delivered over a 3-week period in
participants’ natural environment. Assessments were completed at baseline, immediately
after treatment, and at 3-month follow-up. Analysis began April 6, 2018, and was intention
to treat.
INTERVENTION Self-guided app-based VR CBT.
MAIN OUTCOMES AND MEASURES The primary outcome measure was the Acrophobia
Questionnaire. The hypothesis was formulated prior to data collection.
RESULTS In total, 193 participants (129 women [66.84%]; mean [SD] age, 41.33 [13.64] years)
were randomly assigned to intervention (n = 96) or a wait-list control group (n = 97). An
intent-to-treat analysis showed a significant reduction of acrophobia symptoms at posttest
at 3 months for the VR-CBT app compared with the controls (b = –26.73 [95% CI, −32.12 to
−21.34]; P < .001; d = 1.14 [95% CI, 0.84 to 1.44]). The number needed to treat was 1.7.
Sensitivity and robustness analysis confirmed these findings. Pretreatment attrition was
22 of 96 (23%) because of smartphone incompatibility. Of the 74 participants who started
using the VR-CBT app, 57 (77%) completed the intervention fully.
CONCLUSIONS AND RELEVANCE A low-cost fully self-guided app-based virtual reality cognitive
behavioral therapy with rudimentary virtual reality goggles can produce large acrophobia
symptom reductions. To our knowledge, this study is the first to show that virtual reality
acrophobia treatment can be done at home without the intervention of a therapist.
TRIAL REGISTRATION Trialregister.nl identifier: NTR6442
JAMA Psychiatry. 2019;76(7):682-690. doi:10.1001/jamapsychiatry.2019.0219
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A ccess to evidence-based psychological treatment formental health disorders is a global challenge becauseof high-treatment costs1 and the limited availability of
mental health professionals.2 Treatment coverage is below 50%
and usually substantially lower.2 Novel technologies may con-
tribute to accessible and affordable treatment options in im-
portant ways.
Specific phobias rank among the most prevalent mental
health disorders,3,4 of which acrophobia is the most preva-
lent of all subtypes.5,6 Worryingly, specific phobias may in-
crease the risk of developing other anxiety disorders7 and
major depression.8
Several evidence-based therapies exist, most of which use
cognitive behavior therapy (CBT), involving exposing indi-
viduals to their feared object or situation.9 An emergent form
of exposure is virtual reality exposure therapy (VRET), in which
immersive virtual environments replace real-life exposure
settings.10 Meta-analyses indicate VRET is as effective as
conventional exposure therapy11-13 with large effect sizes11-15
and similar dropout and deterioration rates.11,12,16,17 How-
ever, VRET has thus far required therapist involvement and
uses high-end virtual reality (VR) equipment.18
Recently, efforts toward reducing therapist involvement
using VRET have been undertaken. A randomized clinical trial19
targeting acrophobia demonstrated a large effect size (d = 2.0)
but still required expensive technology, and treatment was de-
livered in a clinic under the supervision of a therapist. Hence,
the relative effect of the intervention itself remains unknown
and costs are not reduced. A literature search (eAppendix 1 in
Supplement 2) yielded no results on previous studies using a
mobile app for acrophobia treatment (except for the present
study’s protocol20).
The present study tested the effectiveness and user friend-
liness of ZeroPhobia, a fully self-guided VR CBT for acrophobia
symptoms that is delivered through a smartphone. To
ensure scalability, the VR-CBT app relies on participants’ own
smartphone and basic ($10) cardboard VR goggles, while the pro-
gram can be followed at home. We hypothesized that the app
would be associated with greater overall response at posttest
compared with a wait-list control group and that the treat-
ment gains would be maintained at 3-month follow-up. For
robustness, we included a second questionnaire assessing
acrophobia symptoms. Depressive symptoms were examined
to assess whether the VR-CBT app could also influence
depression levels. We also tested whether variation in per-
ceived user friendliness, general anxiety, and cyber sickness
when using the app affected acrophobia symptoms at
posttest.
Methods
Study Design and Procedure
In this single-blind randomized clinical trial, participants were
recruited from the Dutch general population through web-
sites, magazines, and local media. Ethical approval was re-
ceived from the Medical Ethics Committee of the Vrije Uni-
versiteit Medical Center (the trial protocol has been previously
published20 and is available in Supplement 1). Participants pro-
vided written informed consent by email or mail.
Participants
To be considered for inclusion, individuals had to score at
least 45.45 on the Acrophobia Questionnaire (AQ)–Anxiety
(1 SD below the mean of a previous acrophobic sample),21,22
have access to an Android smartphone (Android version 5.1
Lollipop or higher, 4.7- to 5.5-inch screen, and gyroscope),
be aged 18 to 65 years, and have provided informed consent.
Exclusion criteria were insufficient Dutch language skills,
current phobia treatment or receiving psychotropic medica-
tion, or having severe depression (total score >19 on the
Patient Health Questionnaire–9 item23) or suicidality (score
≥3 on the Web Screening Questionnaire24). Enrollment com-
menced March 24 and ceased September 28, 2017. Analysis
began in April 2018.
Randomization and Masking
A randomization list was created with Random Allocation
Software25 using block randomization of 6, 8, 10, and 12
blocks at an allocation ratio of 1:1. Participants were ran-
domized into 2 groups: intervention or wait-list. The ran-
domization list was kept by an independent researcher who
revealed the next randomization outcome after every inclu-
sion, thus ensuring that the research team was blind for
treatment allocation. All materials were completed online
without researcher intervention.
Intervention: VR-CBT App
Participants received 6 animated CBT-based modules using
2-dimensional animations and a voice-over provided by a
virtual therapist. The modules took between 5 and 40 min-
utes to complete. Participants were asked to complete the
entire intervention within 3 weeks. Aside from the psycho-
education and CBT techniques, the VR-CBT app included a
gamified immersive VR environment and four 360° videos
covering the entire exposure spectrum. The participants
started using VR and 360° videos from module 3 onwards
and navigated through the virtual environment using gaze
Key Points
Question Is fully self-guided app-based virtual reality cognitive
behavior therapy using low-cost (cardboard) virtual reality goggles
user friendly and effective in reducing acrophobia symptoms
compared with a wait-list control group?
Findings In a single-blind randomized clinical trial that included
193 participants with acrophobia symptoms, app-based therapy
demonstrated a large and significant reduction in acrophobia
symptoms compared with wait-list controls and was rated as user
friendly.
Meaning Acrophobia cognitive behavioral therapy can be
effectively delivered without therapist intervention through
standard smartphones and low-cost virtual reality goggles at a
fraction of the cost of current face-to-face treatment or high-end
virtual reality exposure therapy.
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control. Because previous research found better effects
when the treatment was delivered twice a week compared
with once a week,26 the 6 app modules were offered over a
period of 3 weeks. However, participants could practice
with the VR-CBT app as often as they wanted. During the
3-week period, participants received weekly standardized
motivational emails with reminders to start or continue
with the app (Donker et al20 includes intervention details;
eFigure in Supplement 2 includes VR screen shots). The VR
environment was created with the Unity game engine (ver-
sion 2017.3.0f3; Unity Technologies).
Outcomes
All measures at baseline, posttest, and 3-month follow-up were
completed online. The participants were asked for demo-
graphic information and at each assessment point, whether
they received any other professional acrophobia treatment.
The primary outcome was the AQ.21 In a previous study,
the mean (SD) AQ-Anxiety scores in a Dutch population were
59.06 (17.12).27 Secondary outcomes included the Attitudes
Toward Heights Questionnaire,28 the Beck Anxiety Inventory,29
the System Usability Scale30 to assess user friendliness, the
Igroup Presence Questionnaire31 to assess presence in VR,
Mastery32 to assess subjective feelings of control, and the
Patient Health Questionnaire–9 item23 to assess depressive
symptoms. The use of professional treatment during the
VR-CBT app, the 3-item Simulator Sickness Questionnaire
(SSQ),33,34 and vision impairment (eg, wearing glasses) were
included as control variables. The SSQ is commonly used to
assess simulator sickness but not in the context of anxiety treat-
ment; the items completely overlap with anxiety symptoms
(eg, nausea, dizziness).19 We used a simple raw score of whether
the symptom was present or not. All assessments were pro-
grammed with Survalyzer software.35
Study Power
The primary outcome measure, the AQ, was used for the power
calculations. In previous meta-analyses in which VRET vs a
wait-list control group was compared using the AQ, effect sizes
ranged from 0.93 to 1.23.12,14,15 However, the unguided na-
ture of the VR-CBT app, the use of low-end equipment, and
the lack of comparable studies led us to opt for a conservative
estimate of Cohen d = 0.50. With 80% power at a 5% signifi-
cance level (2-sided), 64 participants in each condition were
required (128 participants in total). Because of the high drop-
out rates often encountered in self-guided interventions,36 we
Figure 1. Flow of Participants
663 Patients applied for study on website
539 Assessed for eligibility
346 Excluded
167 Not meeting inclusion criteria
3 Scored >19 on PHQ
3 Not in 18-65 y age range
1 Currently in treatment
86 No informed consent
69 Did not fill in complete screening
13 Declined to participate
11 Did not fill in baseline
112 Scored <45.45 on AQ
46 Ineligible phone
124 Excluded (ineligible phone, eg, iPhone)
193 Randomized
96 Allocated to ZoroPhobia
75 Received allocated intervention
21 Did not receive allocated intervention
21 Technical problems
1 Illness
97 Allocated to waiting list control group
97 Analyzed96 Analyzed
57 Filled in posttest
17 Lost to posttest
16 Unknown
1 Cardboard problems
47 Filled in follow-up
10 Lost to follow-up (unknown reasons)
87 Filled in posttest
10 Lost to posttest (unknown reasons)
97 Access granted to ZeroPhobia intervention
AQ indicates Acrophobia
Questionnaire; PHQ, Patient Health
Questionnaire.
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estimated a 40% dropout rate, meaning 180 participants were
required.20
Statistical Analyses
Demographic and clinical characteristics were compared be-
tween the intervention and the wait-list control groups, with
χ2 or variance analysis as appropriate. To assess whether pre-
treatment attrition (participants who failed to commence treat-
ment after randomization37) and dropout (participants who
discontinued treatment after commencing treatment37) were
nonrandom, a balancing table was constructed comparing
background characteristics, prescores, and other covariates be-
tween participants with and without missing outcome obser-
vations. Missing outcome observations were accounted for by
using a single best regression-imputed value. Missing out-
come values for the pretreatment attrition sample were im-
puted using the wait-list control sample, whereas for the drop-
out sample initial treatment assignment was used. The
empirical evaluation was performed on an intention-to-treat
(ITT) basis, using ordinary least squares regression models with
prescores and background characteristics included. Standard-
ized effect sizes (Cohen d) and confidence intervals were cal-
culated for each end point.
Two additional robustness analyses were performed. First,
because nonrandom sample attrition may bias the estimated
treatment effects, nonparametric treatment effect bounds were
estimated.38 Second, multiple imputation using an iterative
Markov chain Monte Carlo method based on initial treatment
assignment was performed to infer the statistical signifi-
cance of the reported differences between the intervention and
control groups. Furthermore, potential heterogeneity and
mechanisms of effective treatment were addressed by esti-
mating how treatment effects vary with prescores, general
anxiety, and experiences when using the app. We also ana-
lyzed the predicted reductions in the posttest for 10-point bins
of prescores using regression analyses to examine whether se-
verity at baseline AQ predicts outcome. Sensitivity analyses
using participants who completed posttest or follow-up after
the intervention examined whether there was a difference in
the results compared with the ITT analysis.39 We explor-
atively assessed clinically meaningful change on the AQ using
the clinically significant change formula (method C40) with an
AQ score less than 31.67.41 The reliable change criterion was
assessed based on the AQ pretest SD scores with a Cronbach α
of .91. This yielded an SE of change of 7.98, with a correspond-
ing reliable change criterion on the AQ score of 15.65
(7.98 × 1.96).42,43 We also assessed the number needed to treat
using the formula by Furukawa et al44 based on the effect size
of the AQ. Two-sided P value less than .05 indicated statisti-
cal significance. Stata version 14.2 (StataCorp) was used for the
analyses except for number needed to treat, which was con-
ducted in R version 3.4.3 (R Project for Statistical Comput-
ing). A data monitoring committee was not required by the eth-
ics committee because of the expected low safety risk of the
participants.
Deviations From the Original Protocol
We deviated on some issues from the ethics protocol (Supple-
ment 1). For details, see eAppendix 2 in Supplement 2.
Results
Sample Characteristics
Of 663 individuals who signed up for participation, 291 were
ineligible and excluded from participation. In total, 193
participants filled in the baseline assessment and were
randomly assigned to the VR-CBT app (n = 96) or wait-list







Age, mean (SD), y 41.53 (13.73) 41.12 (13.62)
Female, No. (%) 66 (68.75) 63 (64.95)
Education, No. (%)
None or primary 2 (2.08) 0 (0)
Secondary 10 (10.42) 8 (8.25)
Postsecondary 84 (87.50) 89 (91.75)
Psychotropic medication,a
No. (%)
1 (1.04) 4 (4.12)
Primary outcome, mean (SD) Baseline Baseline
AQ-Total 85.16 (18.42) 84.18 (18.25)
AQ-Anxiety 68.62 (14.53) 67.91 (14.44)
AQ-Avoidance 16.54 (5.19) 16.27 (4.83)
Secondary outcomes,
mean (SD)
ATHQ 44.89 (8.72) 44.47 (9.64)
BAI 32.00 (18.69) 33.74 (18.00)
Masteryb 25.56 (7.59) 26.66 (5.81)
PHQ 2.29 (3.31) 2.23 (3.01)
Abbreviations: AQ, Acrophobia Questionnaire; ATHQ, Attention to Height
Questionnaire; BAI, Beck Anxiety Inventory; PHQ, Patient Health Questionnaire;
VR CBT, virtual reality cognitive behavioral therapy.
a Missing 1 observation.
b A higher score means a higher sense of mastery.
Table 2. Inferential Statistics of Treatment Outcome Measures,









AQ-Total 48.46 (24.34) 74.69 (21.55)
AQ-Anxiety 39.55 (19.12) 60.41 (17.02)
AQ-Avoidance 8.62 (5.73) 14.19 (5.13)
Secondary, mean (SD)
ATHQ 32.83 (12.71) 45.16 (9.73)
BAI 33.56 (8.98) 37.93 (13.95)
Masterya 28.02 (4.10) 27.54 (4.86)
PHQ 2.46 (2.34) 2.87 (3.48)
Abbreviations: AQ, Acrophobia Questionnaire; ATHQ, Attention to Height
Questionnaire; BAI, Beck Anxiety Inventory; PHQ, Patient Health Questionnaire;
VR CBT, virtual realtiy cognitive behavioral therapy.
a A higher score means a higher sense of mastery.
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control (n = 97). The pretreatment attrition rate was 23% in the
app condition because of illness (1 [1%]) or an incompatible
smartphone (21 [22%]). Several participants with smart-
phones lacking a gyroscope (required for experiencing VR) were
erroneously included. To ensure that this did not jeopardize
randomization, these participants were included in the ITT
analyses, and Lee bounds38 were estimated to address poten-
tial bias. Figure 1 shows the participant flowchart.
Baseline demographics are provided in Table 1. Data were
balanced between the groups. None of the participants re-
ported receiving professional acrophobia treatment at base-
line, posttest, or follow-up.
Treatment Adherence and Attrition
There were no significant differences in the demographics
between participants (n = 193) and those who were ineli-
gible or chose not to participate (n = 346) (data not shown).
In the intervention group, 59% (57 of 96) of the participants
completed the posttest and 49% (47 of 96) completed
follow-up, compared with 91% (87 of 97) posttest responses
for the wait-list group. Attrition (22 of 96 [23%]) and drop-
out (17 of 96 [18%]) were not related to background charac-
teristics, prescores, and other covariates (eTable 1 in Supple-
ment 2), as indicated by the likelihood ratio test for
predicting missing outcomes (χ2 (9) = 3.47; P = .94), sup-
porting the assumption that outcomes are missing com-
pletely at random.45
Primary Outcome
The intervention condition showed a significant reduction in
acrophobia symptoms compared with the control on the AQ
in the ITT analysis at posttest (b = −26.73 [95% CI, −32.12 to
−21.34]; t191 = −9.79; P < .001; adjusted R2 = 0.52) with an ef-
fect size of d = 1.14 (95% CI, 0.84-1.44). The number needed
to treat was 1.7 (Table 2 and Table 3).
Secondary Outcomes
The results of the ITT analyses (Table 3) demonstrated a sig-
nificant intervention effect compared with the controls on
acrophobia symptoms, Attention to Height Questionnaire
(b = −12.59; t182 = −8.92; P < .001; d = 1.091; 95% CI, 0.787-
1.393), general anxiety symptoms, Beck Anxiety Inventory
(b = −3.87; t182 = −2.62; P < .001; d = 0.37; 95% CI, 0.087-
656), and a greater sense of mastery (b = 1.01; t182 = −2.00;
P = .047; d = −0.11; 95% CI, −0.389 to 0.176). Depressive
symptoms did not change significantly between both
groups, Patient Health Questionnaire–9 item (b = −0.49;
t182 = −1.58; P ≥ .99; d = 0.14; 95% CI, −0.143 to 0.422).
Robustness and Sensitivity Analyses
When estimating the Lee bounds,38 the resulting upper and
lower bounds (model 2) indicated that the treatment effect on
the primary outcome measure (AQ) remained statistically
significant. The ITT estimate in model 1 (b = −26.73, SE = 2.73)
was close to the conservative upper Lee bound (b = −22.34,
SE = 4.55) after imputing outcomes for the attrition sample
using wait-list control participants. Applying multiple impu-
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on initial treatment assignment yielded somewhat bigger SEs
(model 3), but statistical significance of the ITT effect on AQ
was maintained (d = 1.53; 95% CI, 1.15-1.91; Table 3).
Heterogeneous Treatment Effects and Mechanisms
Adding an interaction term to the ITT treatment estimation
model of Table 3 revealed that treatment effectiveness re-
lated positively to baseline acrophobia symptoms (ie, as a modi-
fier) (b = –0.306; SE = 0.15; P = .04), indicating higher poten-
tial benefits for participants with more severe acrophobia
symptoms (eTable 3 in Supplement 2).
The experience-related results indicate that a reduction in
acrophobia symptoms tends to be larger when the usability of
the app was higher (System Usability Scale), when the feeling
of being present in the virtual environment was higher
(Igroup Presence Questionnaire), and when participants ex-
perienced more symptoms of cyber sickness (SSQ) (Figure 2).
The robustness analysis further confirmed that the VR-CBT
app had an impact on the anxiety for heights and that the
general anxiety effect did not drive the results (eTable 4 in
Supplement 2). eTable 5 in Supplement 2 provides regression-
predicted reductions in posttest for 10-point bins of pre-
scores suggesting that moderation is quantitative. Those with
relatively low levels of baseline acrophobia did benefit signifi-
cantly from the treatment.
Complete Cases
For individuals who returned the posttest, the between-
group AQ effect size was d = 1.53 (95% CI, 1.15-1.91; number
needed to treat: 1.4), and for the app individuals, the
within-group effect size was d = 2.68 (95% CI, 2.09-3.22)
between baseline and follow-up. Effect sizes on secondary
outcomes for app individuals were also large (eTable 2 in
Supplement 2). The VR-CBT app participants’ total mean
(SD) Igroup Presence Questionnaire score was 42.69 (10.40)
(range, 14-70).
Exploratory Analysis
For individuals who returned the AQ posttest (n = 56), all par-
ticipants showed reliable change. Furthermore, 44 of 56 (79%)
experienced clinically significant change, a change of 57.97 or
more points on the AQ.
User Friendliness and Adverse Effects
The VR-CBT app was rated as user friendly (mean [SD],
75.35 [14.74], n = 55) and can be interpreted as a good and
usable system.22 No deterioration or negative effects as
defined by Rozental et al46 were identified, except for 24
participants who reported 1 or more symptoms of transient
cyber sickness.
Discussion
To our knowledge, this randomized clinical trial tests the first
fully self-guided treatment for acrophobia. We showed that an
app-based VR-CBT program using low-cost VR goggles is both
effective and user friendly. Large reductions in acrophobia
Figure 2. Heterogeneous Treatment Effects (n = 193) With Respect to Initial Acrophobia Score
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No. of Cyber Sickness Symptoms
Cyber SicknessD
1 2 3 4 5
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symptoms on both the self-reported primary outcome mea-
sure AQ and secondary outcome measure Attention to Height
Questionnaire were obtained. At 3-month follow-up, the re-
sults were maintained for the intervention group as demon-
strated by the large within-group effect size. Importantly, these
findings are in line with previous meta-analyses of guided VR
acrophobia studies using high-end VR equipment12,14,15 and
similar or better compared with therapist-guided exposure in
vivo.47,48 In the current study, dropout rates were similar com-
pared with dropout rates in previous VR studies.16 The app par-
ticipants also experienced a greater reduction in general anxi-
ety and an increased sense of mastery compared with the
controls. As expected, because the baseline level of depres-
sion was low, the symptoms did not decrease; hence, there
were no between-group differences. App participants per-
ceived the VR environment as realistic although these results
are slightly lower compared with previous research.49 This
might be because of the quality of the cardboard VR goggles.
However, the VR-CBT app was rated as user friendly and a good
and usable system. Interestingly, the participants who expe-
rienced more cyber sickness also experienced a larger reduc-
tion in acrophobia symptoms. This might be an artifact of the
SSQ because it overlaps with symptoms of anxiety. For expo-
sure to be beneficial, experiencing anxiety is required. There-
fore, the SSQ might not be a valid measure of cyber sickness
for treating anxiety.
Strengths and Limitations
One of the key strengths of the present study was its ecological
validity because the intervention was conducted in the partici-
pants’ natural environments instead of a research laboratory.
Furthermore, participants received no guidance when using the
VR-CBT app or filling in assessments, thereby ruling out any in-
fluence of human contact. Another strength was that the miss-
ing outcome observations for participants assigned to treat-
ment to the VR-CBT app but unable to use the app because of
incompatible smartphones were based on wait-list control group
characteristics (ie, no treatment effect was imputed), yielding
conservative overall treatment effect estimates. Furthermore,
the ITT design has strong credibility in terms of aggregate ef-
fects when the intervention is scaled and adopted in real life.
The current study had several limitations. First, attrition
was relatively high in the intervention condition because of
incompatible smartphones. However, attrition was statisti-
cally unrelated to all observable characteristics at baseline. To
retain a balanced experimental sample, the results were im-
puted for missing participants using regression-based impu-
tation. Robustness and sensitivity analyses confirmed that
potential bias concerns and precision concerns did not com-
promise the statistical significance of the results. Second, the
data rely exclusively on self-reported measurements. How-
ever, the behavioral measurement effect sizes were similar to
those calculated from other self-reported measures.13 Be-
cause the AQ has no validated cutoff scores, we were unable
to provide results on the clinical threshold for acrophobia. We
did not include a diagnostic interview because we wanted to
isolate the true effect of VR; even in the assessment phase, hu-
man involvement may already have influenced the results.50,51
Third, because our follow-up period was only 3 months and
because of dropout, the results are exploratory, and longer-
term effects remain unknown. Fourth, the generalizability of
the results is limited to Dutch Android smartphone users. How-
ever, most of the Dutch population (57%) uses Android.52
Future research is needed to replicate the VR-CBT app to
draw firm conclusions about its effectiveness, compare the app
directly with high-end VRET and exposure in vivo treatment,
examine its long-term effects, determine cost effectiveness
compared with treatment as usual, and examine whether the
app can also be effective in the treatment of other phobias and
mental health disorders.
Conclusions
In sum, our findings support the hypothesis that a fully self-
guided app-based VR-CBT, which can be done at home at a frac-
tion of the cost of existing evidence-based treatment op-
tions, strongly reduces acrophobia symptoms. The current
study adds to the development of innovative and scalable de-
livery methods of evidence-based treatments and underlines
that new technologies have the potential to transform men-
tal health care worldwide.
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